Editas Medicine, Inc.

EDIT
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001650664

Price chart

Open-market purchases and sales by EDIT insiders, newest first.

Insider trades
Filed (ET)Trade dateInsiderTransactionSharesAvg priceValueShares afterHolding changeFiling
Sep 4, 20264:27 PM ETSep 3, 2026Burkly LindaEVP, CHIEF SCIENTIFIC OFFICERSSaleCommon Stock−709$3.0372−$2.15K61.66K−1.1%SEC10b5-1
Sep 4, 20264:25 PM ETSep 3, 2026Parison AmySVP, Chief Financial OfficerSSaleCommon Stock−453$3.0372−$1.38K13.84K−3.2%SEC10b5-1
Sep 4, 20264:22 PM ETSep 3, 2026O'Neill Gilmore NeilCEOSSaleCommon Stock−5.12K$3.0372−$15.56K243.19K−2.1%SEC10b5-1
Aug 5, 20264:07 PM ETAug 3, 2026Parison AmySVP, Chief Financial OfficerSSaleCommon Stock−678$2.58−$1.75K14.29K−4.5%SEC10b5-1
Jul 29, 20264:51 PM ETJul 28, 2026Burkly LindaEVP, CHIEF SCIENTIFIC OFFICERSSaleCommon Stock−4.93K$2.67−$13.16K62.37K−7.3%SEC10b5-1

The largest institutional positions in EDIT at the end of Q2 2026.

Institutions holding EDIT in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
TCG Crossover Management, LLC11,111,111$36M0.87%+11,111,111New
BlackRock, Inc.10,589,990$34.31M0.00%+1,326,678+14.3%Added
RA CAPITAL MANAGEMENT, L.P.8,889,000$28.8M0.25%+8,889,000New
COMMODORE CAPITAL LP8,889,000$28.8M1.72%+8,889,000New
ADAR1 Capital Management, LLC8,889,000$28.8M1.35%+8,889,000New